



## Sage Therapeutics to Participate in SVB Leerink's 3rd Annual CNS Forum

June 24, 2021

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 24, 2021-- Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will participate in a fireside chat at SVB Leerink's 3rd Annual CNS Forum on June 29<sup>th</sup> at 4:15pm ET.

A live webcast of each presentation can be accessed on the investor page of Sage's website at [investor.sagerx.com](http://investor.sagerx.com). A replay of the webcasts will be available approximately two hours after the completion of the event and will be archived for up to 30 days.

### About Sage Therapeutics

Sage Therapeutics is a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain. We are pursuing new pathways with the goal of improving brain health, and our depression, neurology and neuropsychiatry franchise programs aim to change how brain disorders are thought about and treated. Our mission is to make medicines that matter so people can get better, sooner. For more information, please visit [www.sagerx.com](http://www.sagerx.com).

View source version on [businesswire.com](http://businesswire.com): <https://www.businesswire.com/news/home/20210624005173/en/>

### Investor Contact

Jeff Boyle  
617-949-4256  
[Jeff.Boyle@sagerx.com](mailto:Jeff.Boyle@sagerx.com)

### Media Contact

Maureen L. Suda  
617-949-4289  
[maureen.suda@sagerx.com](mailto:maureen.suda@sagerx.com)

Source: Sage Therapeutics, Inc.